Abstract: Ovarian cancer is one of the common malignant tumors in gynecology. Because the ovary is located in the deep part of the pelvic cavity, it is small in size and lacks typical symptoms and signs when they are diseased. When ovarian cancer is found, most of them are advanced. The high recurrence rate, high mortality rate and low survival rate of ovarian cancer pose a serious threat to women′s life. Among them, epithelial cancer is the most common type, accounting for 50%-70% of ovarian malignant tumors, and it is sensitive to chemotherapy. Surgery and chemotherapy are the main treatments for ovarian cancer. Chemotherapy includes preoperative neoadjuvant chemotherapy(NAC) and postoperative adjuvant chemotherapy. The first-line chemotherapy for ovarian cancer is combined chemotherapy based on platinum and paclitaxel. With the further study of chemotherapy, most patients were found to be platinum-sensitive while about 20% of patients had platinum resistance. Regardless of the initial response of patients to chemotherapy, most patients will inevitably have resistance to platinum treatment in the process of disease, which has a great influence on the effects of chemotherapy and the progression-free survival (PFS) and the overall survival (OS) of patients. There are many reasons for platinum resistance, including the increase of drug use, the decrease of drug transport capacity, long period of NAC, impaired DNA repair and changes in apoptotic processes, but the main mechanism needs further study. This is a review of the current situation and progress of chemotherapy for ovarian cancer.

Key words: Ovarian neoplasms, Carcinoma, Drug therapy, combination, Antineoplastic combined chemotherapy protocols, Chemoradiotherapy, adjuvant, Platinum compounds;, Drug resistance, neoplasm